Dengue hemorrhagic fever with special emphasis on immunopathogenesis
- PMID: 17645944
- DOI: 10.1016/j.cimid.2007.05.010
Dengue hemorrhagic fever with special emphasis on immunopathogenesis
Abstract
Dengue virus infections are a serious cause of morbidity and mortality in most tropical and subtropical areas of the world; Southeast and South Asia, Central and South America, and the Caribbean. Dengue virus infection can be asymptomatic or causes two forms of illness, dengue fever (DF) and dengue hemorrhagic fever (DHF), which is the severe form of dengue illness and often fatal. Pathogenesis of DHF has been analyzed, and two mechanisms are considered to be responsible. These include dengue serotype cross-reactive immune responses and virulence of the virus. The immunopathological mechanisms include a complex series of immune responses. Rapid increase in the levels of cytokines, especially TNF-alpha, and chemical mediators play a key role in inducing unique clinical manifestations of DHF such as plasma leakage, shock, and hemorrhagic manifestations. It is understood that the process is initiated by infection with a virulent dengue virus, often in the presence of antibodies that enhance dengue virus infection in secondary infection, and then triggered by rapidly elevated cytokines and chemical mediators that were produced by intense immune activation. However, complete understanding of the entire pathological mechanism is far from complete, and further studies are still needed.
Similar articles
-
Alternate hypothesis on the pathogenesis of dengue hemorrhagic fever (DHF)/dengue shock syndrome (DSS) in dengue virus infection.Exp Biol Med (Maywood). 2008 Apr;233(4):401-8. doi: 10.3181/0707-MR-198. Exp Biol Med (Maywood). 2008. PMID: 18367628 Review.
-
Immunopathological mechanisms in dengue and dengue hemorrhagic fever.Curr Opin Infect Dis. 2006 Oct;19(5):429-36. doi: 10.1097/01.qco.0000244047.31135.fa. Curr Opin Infect Dis. 2006. PMID: 16940865 Review.
-
Dengue fever and dengue haemorrhagic fever: challenges of controlling an enemy still at large.Rev Med Virol. 2001 Sep-Oct;11(5):301-11. doi: 10.1002/rmv.324. Rev Med Virol. 2001. PMID: 11590668 Review.
-
Progress for dengue virus diseases. Towards the NS2B-NS3pro inhibition for a therapeutic-based approach.FEBS J. 2007 Jun;274(12):2986-3002. doi: 10.1111/j.1742-4658.2007.05831.x. Epub 2007 May 17. FEBS J. 2007. PMID: 17509079
-
Dengue and dengue hemorrhagic fever among adults: clinical outcomes related to viremia, serotypes, and antibody response.J Infect Dis. 2008 Mar 15;197(6):817-24. doi: 10.1086/528805. J Infect Dis. 2008. PMID: 18269315
Cited by
-
Primary dengue haemorrhagic fever in patients from northeast of Brazil is associated with high levels of interferon-β during acute phase.Mem Inst Oswaldo Cruz. 2016 May 24;111(6):378-84. doi: 10.1590/0074-02760150453. Mem Inst Oswaldo Cruz. 2016. PMID: 27223651 Free PMC article.
-
Variation in inflammatory/regulatory cytokines in secondary, tertiary, and quaternary challenges with dengue virus.Am J Trop Med Hyg. 2012 Sep;87(3):538-47. doi: 10.4269/ajtmh.2012.11-0531. Epub 2012 Jul 16. Am J Trop Med Hyg. 2012. PMID: 22802438 Free PMC article.
-
Induction of a protective response in mice by the dengue virus NS3 protein using DNA vaccines.PLoS One. 2011;6(10):e25685. doi: 10.1371/journal.pone.0025685. Epub 2011 Oct 21. PLoS One. 2011. PMID: 22031819 Free PMC article.
-
Dengue: where are we today?Malays J Med Sci. 2009 Jul;16(3):4-11. Malays J Med Sci. 2009. PMID: 22589659 Free PMC article.
-
Complement and its role in protection and pathogenesis of flavivirus infections.Vaccine. 2008 Dec 30;26 Suppl 8:I100-7. doi: 10.1016/j.vaccine.2008.11.061. Vaccine. 2008. PMID: 19388173 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous